References
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology130, 1480–1491 (2006).
- Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice. Am. J. Gastroenterol.95, 3176–3183 (2000).
- Mertz H, Morgan V, Tanner G et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology118, 842–848 (2000).
- Chadwick V, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology122, 1778–1783 (2002).
- Cann PA, Read NW, Brown C, Hobson A, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut24, 405–411 (1983).
- Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology133, 24–33 (2007).
- Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BMR, Moayyedi P. Yield of diagnostic tests for celiac disease in subjects with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch. Intern. Med.169, 651–658 (2009).
- Wedlake L, A’Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther.30, 707–717 (2009).
- Leeds JS, Hopper AD, Sidhu R et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin. Gastroenterol. Hepatol.8, 433–438 (2010).
- Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol.7, 68–72 (2009).
- King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet352, 1187–1189 (1998).
- Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann. Intern. Med.145, 557–563 (2006).
- Pimentel M, Lembo A, Chey WD et al. Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American Phase 3 trials (Target 1 and Target 2). Gastroenterology138(Suppl. 1), S64–S65 (2010).
- Parodi A, Greco A, Savarino E et al. May breath test be useful in diagnosis of IBS patients? An Italian study. Gastroenterology132(Suppl. 1), A192 (2007).
- Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am. J. Gastroenterol.103, 958–963 (2008).
- Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig. Dis. Sci. DOI: 10.1007/s10620-010-1276-4 (2010) (Epub ahead of print).
- Ford AC, Spiegel BMR, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol.7, 1279–1286 (2009).
- Posserud I, Stotzer P-O, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut56, 802–808 (2007).
- Spiegel BMR, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am. J. Gastroenterol.103, 2972–2976 (2008).
- Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in irritable bowel syndrome. Aliment. Pharmacol. Ther.32, 144–158 (2010).